CY1118642T1 - Παρατεταμενη απελευθερωση μικροκρισταλλικων εναιωρηματων πεπτιδιου - Google Patents
Παρατεταμενη απελευθερωση μικροκρισταλλικων εναιωρηματων πεπτιδιουInfo
- Publication number
- CY1118642T1 CY1118642T1 CY20171100156T CY171100156T CY1118642T1 CY 1118642 T1 CY1118642 T1 CY 1118642T1 CY 20171100156 T CY20171100156 T CY 20171100156T CY 171100156 T CY171100156 T CY 171100156T CY 1118642 T1 CY1118642 T1 CY 1118642T1
- Authority
- CY
- Cyprus
- Prior art keywords
- micro
- long
- peptide
- crystal drive
- term release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η εφεύρεση αναφέρεται σε μια μέθοδο για πρόληψη σχηματισμού γέλης ενός υδρόφοβου πεπτιδίου θέτοντας σε επαφή το υδρόφοβο πεπτίδιο με ένα αντίθετο ιόν σε μια ποσότητα και μια γραμμομοριακή αναλογία επαρκή για να παρασχεθεί ένα ρευστό, γαλακτώδες μικροκρυσταλλικό υδατικό εναιώρημα του πεπτιδίου χωρίς σχηματισμό γέλης. Η εφεύρεση αναφέρεται επίσης σε ένα ρευστό, γαλακτώδες μικροκρυσταλλικό υδατικό εναιώρημα ενός υδρόφοβου πεπτιδίου και ενός αντίθετου ιόντος σε νερό, όπου το πεπτίδιο και το αντίθετο ιόν είναι παρόν σε ποσότητες και μια γραμμομοριακή αναλογία επαρκείς για να σχηματίσουν, μετά από ανάμιξη, το εναιώρημα χωρίς σχηματισμό γέλης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31761601P | 2001-09-06 | 2001-09-06 | |
EP02772214A EP1423150B1 (en) | 2001-09-06 | 2002-08-27 | Sustained release of microcrystalline peptide suspensions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118642T1 true CY1118642T1 (el) | 2017-07-12 |
Family
ID=23234486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100156T CY1118642T1 (el) | 2001-09-06 | 2017-02-02 | Παρατεταμενη απελευθερωση μικροκρισταλλικων εναιωρηματων πεπτιδιου |
Country Status (27)
Country | Link |
---|---|
US (5) | US7098305B2 (el) |
EP (2) | EP2198888B1 (el) |
JP (3) | JP2005504787A (el) |
KR (2) | KR20070107161A (el) |
CN (1) | CN100386116C (el) |
AR (1) | AR042592A1 (el) |
AT (1) | ATE463258T1 (el) |
AU (1) | AU2002337025B2 (el) |
BR (1) | BR0212333A (el) |
CA (1) | CA2459309C (el) |
CY (1) | CY1118642T1 (el) |
DE (1) | DE60235896D1 (el) |
DK (1) | DK2198888T3 (el) |
ES (2) | ES2362505T3 (el) |
HK (1) | HK1062148A1 (el) |
HU (1) | HUP0402099A2 (el) |
IL (1) | IL160443A0 (el) |
MX (1) | MXPA04002185A (el) |
NO (1) | NO20040938L (el) |
NZ (1) | NZ531734A (el) |
PL (1) | PL368056A1 (el) |
PT (1) | PT2198888T (el) |
RU (1) | RU2311195C2 (el) |
TW (1) | TWI249409B (el) |
UA (1) | UA79435C2 (el) |
WO (1) | WO2003022243A2 (el) |
ZA (1) | ZA200401390B (el) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
DK1545613T3 (da) * | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
AR044852A1 (es) * | 2003-06-24 | 2005-10-05 | Novartis Ag | Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina |
GB0320806D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
SI1984009T1 (sl) | 2006-01-18 | 2013-02-28 | Qps, Llc | Farmacevtski sestavki z izboljĺ ano stabilnostjo |
BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
WO2008071984A1 (en) * | 2006-12-13 | 2008-06-19 | Ardana Bioscience Limited | Administration of the gonadotropin-releasing hormone antagonist teverelix |
AR067544A1 (es) | 2007-07-16 | 2009-10-14 | Genentech Inc | Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos |
EP2641618A3 (en) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
SG187517A1 (en) | 2008-01-31 | 2013-02-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
CN102046192B (zh) * | 2008-05-07 | 2014-11-19 | 默里昂研究Ⅲ有限公司 | GnRH相关化合物的组合物及制备方法 |
WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
PL2523653T3 (pl) | 2010-01-13 | 2018-09-28 | Ipsen Pharma S.A.S. | Sposób wytwarzania kompozycji farmaceutycznych do przedłużonego uwalniania analogów somatostatyny |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
US8927687B2 (en) | 2010-07-09 | 2015-01-06 | Amylin Pharmaceuticals, Llc | Microcrystalline Y receptor agonists |
CN103476419A (zh) | 2011-01-07 | 2013-12-25 | 梅里翁第三研究有限公司 | 口服投药的含铁药物组合物 |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
EP2823808A1 (en) | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
CN104844694A (zh) * | 2014-02-17 | 2015-08-19 | 深圳翰宇药业股份有限公司 | 一种醋酸加尼瑞克的制备方法 |
AU2014384434B2 (en) | 2014-02-28 | 2016-11-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
HRP20200924T8 (hr) | 2014-09-23 | 2023-07-21 | F. Hoffmann - La Roche Ag | Postupak primjene imunokonjugata anti-cd79b |
CN107205948B (zh) | 2015-01-29 | 2021-12-14 | 诺和诺德股份有限公司 | 包含glp-1激动剂和肠溶衣的片剂 |
EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
KR20220147720A (ko) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
KR20210157482A (ko) | 2017-01-30 | 2021-12-28 | 안테브 리미티드 | 적어도 하나의 gnrh 길항제를 포함하는 조성물 |
US20200129583A1 (en) | 2017-06-30 | 2020-04-30 | Antev Limited | Composition for treating acute urinary retention |
EP3560555A1 (en) | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
US20210196783A1 (en) * | 2018-05-28 | 2021-07-01 | Jiangyin Usun Pharmaceutical Co., Ltd. | New pharmaceutical use |
EP3590524B1 (en) * | 2018-07-05 | 2020-11-04 | Antev Limited | A method of reconstituting a teverelix-tfa composition |
EP3590526A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | A lyophilization process and a teverelix-tfa lyophilizate obtained thereby |
EP3590525A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | Teverelix-tfa composition |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2668866A (en) * | 1951-08-14 | 1954-02-09 | Shell Dev | Isomerization of paraffin wax |
GB1245187A (en) | 1969-02-14 | 1971-09-08 | Continental Can Co | Hot melt adhesive composition |
JPS5242506A (en) | 1975-10-02 | 1977-04-02 | Toa Nenryo Kogyo Kk | Hydrotreating process of petroleum wax |
JPS5335705A (en) * | 1976-09-14 | 1978-04-03 | Toa Nenryo Kogyo Kk | Hydrogenation and purification of petroleum wax |
US4186078A (en) * | 1977-09-12 | 1980-01-29 | Toa Nenryo Kogyo Kabushiki Kaisha | Catalyst and process for hydrofining petroleum wax |
US4239546A (en) * | 1978-07-21 | 1980-12-16 | Petrolite Corporation | Hydrocarbon polymers to improve the hardness of waxes |
US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
US4266737A (en) * | 1979-11-05 | 1981-05-12 | Arrow Converting Equipment, Inc. | Air differential mandrel and method of differentially winding and rewinding tapes |
US4415649A (en) * | 1981-02-25 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Flexographic printing plates containing blended adhesives |
US4839422A (en) * | 1987-12-23 | 1989-06-13 | Exxon Chemical Patents Inc. | Ternary adhesive compositions |
US5110904A (en) * | 1989-08-07 | 1992-05-05 | Abbott Laboratories | Lhrh analogs |
EP0400065B1 (en) | 1988-02-10 | 1997-08-27 | TAP Pharmaceuticals Inc. | Lhrh analog |
JP2672677B2 (ja) | 1989-02-09 | 1997-11-05 | タツプ・フアーマシユーテイカルズ・インコーポレイテツド | Lhrh同族体 |
DE69214818T2 (de) * | 1991-04-25 | 1997-02-27 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten |
JP3523254B2 (ja) * | 1992-10-26 | 2004-04-26 | シュヴァルツ・ファルマ・アクチエンゲゼルシャフト | マイクロカプセルの製造方法 |
EP0673254A4 (en) | 1992-12-04 | 1998-11-18 | Abbott Lab | HORMONE ANTAGONISTS RELEASING LUTEINIZING HORMONE (LHRH) OF MODIFIED DECAPEPTIDES IN POSITION 6. |
WO1994014841A1 (en) | 1992-12-18 | 1994-07-07 | Abbott Laboratories | Lhrh antagonists having modified aminoacyl residues at postions 5 and 6 |
DE4342092B4 (de) | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
CA2178592C (en) | 1993-12-09 | 2009-07-28 | Jurgen Engel | Long-acting injection suspensions and a process for their preparation |
JP3101695B2 (ja) | 1996-07-24 | 2000-10-23 | 日本航空電子工業株式会社 | 軟x線光学素子用多層膜 |
US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
DE19813849A1 (de) * | 1998-03-27 | 1999-09-30 | Degussa | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden |
CO5160256A1 (es) | 1999-02-08 | 2002-05-30 | Zentaris Ag | Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion |
DE10040700A1 (de) * | 2000-08-17 | 2002-02-28 | Asta Medica Ag | Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung |
US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
JP4505750B2 (ja) | 2006-01-27 | 2010-07-21 | 東海ゴム工業株式会社 | 制振装置 |
-
2002
- 2002-02-19 US US10/080,130 patent/US7098305B2/en not_active Expired - Lifetime
- 2002-08-27 IL IL16044302A patent/IL160443A0/xx unknown
- 2002-08-27 BR BR0212333-9A patent/BR0212333A/pt not_active IP Right Cessation
- 2002-08-27 PL PL02368056A patent/PL368056A1/xx unknown
- 2002-08-27 HU HU0402099A patent/HUP0402099A2/hu unknown
- 2002-08-27 NZ NZ531734A patent/NZ531734A/en not_active IP Right Cessation
- 2002-08-27 JP JP2003526373A patent/JP2005504787A/ja active Pending
- 2002-08-27 CN CNB028173775A patent/CN100386116C/zh not_active Expired - Lifetime
- 2002-08-27 RU RU2004110615/15A patent/RU2311195C2/ru not_active IP Right Cessation
- 2002-08-27 DK DK10003046.9T patent/DK2198888T3/en active
- 2002-08-27 WO PCT/EP2002/009537 patent/WO2003022243A2/en active Application Filing
- 2002-08-27 EP EP10003046.9A patent/EP2198888B1/en not_active Expired - Lifetime
- 2002-08-27 CA CA2459309A patent/CA2459309C/en not_active Expired - Lifetime
- 2002-08-27 MX MXPA04002185A patent/MXPA04002185A/es not_active Application Discontinuation
- 2002-08-27 AU AU2002337025A patent/AU2002337025B2/en not_active Ceased
- 2002-08-27 KR KR1020077021972A patent/KR20070107161A/ko not_active Application Discontinuation
- 2002-08-27 PT PT100030469T patent/PT2198888T/pt unknown
- 2002-08-27 EP EP02772214A patent/EP1423150B1/en not_active Expired - Lifetime
- 2002-08-27 AT AT02772214T patent/ATE463258T1/de active
- 2002-08-27 ES ES02772214T patent/ES2362505T3/es not_active Expired - Lifetime
- 2002-08-27 DE DE60235896T patent/DE60235896D1/de not_active Expired - Lifetime
- 2002-08-27 KR KR1020047003371A patent/KR100818904B1/ko active IP Right Grant
- 2002-08-27 UA UA2004031905A patent/UA79435C2/uk unknown
- 2002-08-27 ES ES10003046.9T patent/ES2618777T3/es not_active Expired - Lifetime
- 2002-08-29 TW TW091119713A patent/TWI249409B/zh not_active IP Right Cessation
- 2002-09-05 AR ARP020103358A patent/AR042592A1/es unknown
-
2004
- 2004-02-20 ZA ZA200401390A patent/ZA200401390B/en unknown
- 2004-03-04 NO NO20040938A patent/NO20040938L/no not_active Application Discontinuation
- 2004-07-15 HK HK04105185.0A patent/HK1062148A1/xx not_active IP Right Cessation
-
2006
- 2006-06-12 US US11/450,293 patent/US20060228385A1/en not_active Abandoned
- 2006-06-12 US US11/450,292 patent/US20060229238A1/en not_active Abandoned
-
2010
- 2010-01-28 JP JP2010016716A patent/JP5757686B2/ja not_active Expired - Lifetime
- 2010-06-07 US US12/795,246 patent/US20100239683A1/en not_active Abandoned
-
2011
- 2011-09-01 US US13/224,105 patent/US8415300B2/en not_active Expired - Lifetime
-
2013
- 2013-06-10 JP JP2013122235A patent/JP2013177449A/ja active Pending
-
2017
- 2017-02-02 CY CY20171100156T patent/CY1118642T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118642T1 (el) | Παρατεταμενη απελευθερωση μικροκρισταλλικων εναιωρηματων πεπτιδιου | |
CY1106532T1 (el) | Ετερολογος εκφραση των πρωτεϊνων της neisseria | |
CY1117551T1 (el) | Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου | |
NO20021013D0 (no) | Vandig geldannet blanding som omfatter en blokk-kopolymer inkluderende minst en vannopplöselig blokk og en hydrofob blokk | |
CY1106481T1 (el) | Διαδικασια για την παρασκευη γαβαπεντινης | |
BR0207332A (pt) | Composição de fluido de fraturamento hidráulico, e, processo para gerar fissuras em uma formação subterrânea | |
CY1112330T1 (el) | Πρωτεϊνες συνδεσης gag | |
AR048918A1 (es) | Conjugados de almidon de hidroxietilo y eritropoyetina | |
EA200501863A1 (ru) | Полимерные производные, имеющие специфические атомные структуры | |
CY1109593T1 (el) | Παραγωγα 12,13-κυκλοπροπανο εποθιλονης | |
HN2002000142A (es) | Champues con alcohol behenilo | |
BR0308211A (pt) | Cumarinas úteis como biomarcadores | |
DE50101884D1 (de) | Haarfärbemittel | |
TR200201270T2 (tr) | Epinastin içeren çözeltiler. | |
DOP2001000297A (es) | Nuevas imidazotriazinonas sustituidas | |
ES2183349T3 (es) | Dispersion de fibras de aramida y hojas de aramida. | |
ECSP044862A (es) | Pirenzepine ophthalmic gel | |
AR051251A1 (es) | Composiciones electrodializadas y metodo para tratar soluciones acuosas utilizando electrodialisis | |
DK1147139T3 (da) | Vandig copolymerisatdespersion, fremgangsmåde til fremstilling deraf såvel som anvendelse deraf | |
NO20034531L (no) | Brönnbetjeningsfluid og fremgangsmåte for fremstilling og anvendelse av dette | |
CY1105629T1 (el) | Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv | |
CY1106200T1 (el) | Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους | |
DK1177191T3 (da) | Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer | |
ATE348921T1 (de) | T-verbindung zweier profilstäbe | |
DK1370513T3 (da) | Æblesyreadditionssalte af terbinafin |